As described in more detail in other contributions in this issue of Seminars in Nuclear
Medicine, prostate-specific membrane antigen (PSMA) has become one of the most …

Receptor‐mediated drug delivery presents an opportunity to enhance therapeutic efficiency
by accumulating drug within the tissue of interest and reducing undesired, off‐target effects …

Fibroblast activation protein (FAP) has become an attractive target for diagnosis and
therapy, and a series of FAP inhibitor (FAPI)–based radiotracers has been developed and …

The 18‐membered macrocycle H2macropa was investigated for 225Ac chelation in targeted
alpha therapy (TAT). Radiolabeling studies showed that macropa, at submicromolar …

Peptides and small protein scaffolds are gaining increasing interest as therapeutics.
Similarly to full-length antibodies, they can bind a target with a high binding affinity and …

The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic
strategies. Prostate tumors specifically express the prostate‐specific membrane antigen …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

The prostate-specific membrane antigen (PSMA) has emerged as an attractive prostate
cancer associated target for radiotheragnostic application using PSMA-specific radioligands …

The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains
challenging with current treatment options. The development of more effective therapies is …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …